Single Cell Sequencing in a Randomized Phase 2 open label study of Nivolumav plus standard dose Bevacizumab versus Nivolumav and low dose Bevacizumab and recurrent glioblastoma

Project: Research project

Project Details

StatusFinished
Effective start/end date1/1/19 → 1/1/20

Funding

  • Musella Foundation: $100,000.00